Kennebec Savings Bank lifted its position in shares of Danaher Corporation (NYSE:DHR – Free Report) by 5.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 3,211 shares of the conglomerate’s stock after buying an additional 159 shares during the period. Kennebec Savings Bank’s holdings in Danaher were worth $634,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of DHR. Nuveen LLC purchased a new position in shares of Danaher during the first quarter valued at approximately $833,941,000. Invesco Ltd. raised its stake in Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the period. Baird Financial Group Inc. raised its stake in Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after purchasing an additional 1,072,617 shares during the period. Generation Investment Management LLP raised its stake in Danaher by 33.2% during the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock worth $651,515,000 after purchasing an additional 791,662 shares during the period. Finally, Parnassus Investments LLC raised its stake in Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock worth $784,745,000 after purchasing an additional 722,636 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Insider Transactions at Danaher
In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 11.10% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
View Our Latest Research Report on Danaher
Danaher Stock Performance
Danaher stock opened at $212.92 on Thursday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.41. The company has a market capitalization of $152.46 billion, a price-to-earnings ratio of 45.30, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm’s fifty day moving average price is $199.85 and its 200 day moving average price is $197.42.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the previous year, the firm posted $1.72 EPS. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.
Danaher Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is 27.23%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- Why is the Ex-Dividend Date Significant to Investors?
- Datavault AI: The New AI Contender Backed by Big Funding
- Why Are These Companies Considered Blue Chips?
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- What is a Stock Market Index and How Do You Use Them?
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.